News Analysis / Quadrivalent Human Papillomavirus vaccine (qHPV)
Published on: July 13, 2022
Source: The Hindu
Context:
Serum Institute of India plans to launch its indigenously-developed vaccine to prevent cervical cancer in women.
About
The Drugs Controller General of India (DCGI) recently granted market authorisation to Serum Institute of India (SII) to manufacture the indigenously-developed India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer.
Cervical Cancer:
Cervical cancer develops in a woman's cervix (the entrance to the uterus from the vagina).
Almost all cervical cancer cases (99%) are linked to infection with high-risk human papillomaviruses (HPV), an extremely common virus transmitted through sexual contact.
Although most infections with HPV resolve spontaneously and cause no symptoms, persistent infection can cause cervical cancer in women.
When diagnosed, cervical cancer is one of the most successfully treatable forms of cancer, as long as it is detected early and managed effectively.
Cervical cancer in India ranks as the second most frequent cancer among women between 15 and 44 years of age.
Symptoms:
Early-stage cervical cancer generally produces no signs or symptoms. Signs and symptoms of more-advanced cervical cancer include:
Causes:
Cervical cancer begins when healthy cells in the cervix develop changes (mutations) in their DNA.
A cell's DNA contains the instructions that tell a cell what to do.
Healthy cells grow and multiply at a set rate, eventually dying at a set time.
The mutations tell the cells to grow and multiply out of control, and they don't die. The accumulating abnormal cells form a mass (tumor).
Cancer cells invade nearby tissues and can break off from a tumor to spread (metastasize) elsewhere in the body.
It isn't clear what causes cervical cancer, but it's certain that HPV plays a role.
